stoxline Quote Chart Rank Option Currency Glossary
  
Lyell Immunopharma, Inc. (LYEL)
14.8903  -0.64 (-4.12%)    08-24 15:03
Open: 15.3
High: 15.49
Volume: 43,621
  
Pre. Close: 15.53
Low: 14.61
Market Cap: 365(M)
Technical analysis
2026-08-24 2:47:05 PM
Short term     
Mid term     
Targets 6-month :  20.03 1-year :  23.39
Resists First :  17.14 Second :  20.03
Pivot price 14.53
Supports First :  14.24 Second :  12.44
MAs MA(5) :  15.48 MA(20) :  14.17
MA(100) :  16.54 MA(250) :  19.32
MACD MACD :  0.4 Signal :  0.2
%K %D K(14,3) :  57.6 D(3) :  65.7
RSI RSI(14): 55.1
52-week High :  45 Low :  10.56
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ LYEL ] has closed below upper band by 35.1%. Bollinger Bands are 32.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 16.18 - 16.27 16.27 - 16.36
Low: 15.11 - 15.22 15.22 - 15.33
Close: 15.36 - 15.53 15.53 - 15.68
Company Description

Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The company’s lead product candidate include rondecabtagene autoleucel, an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development, which is in pivotal PiNACLE trial in the 3L+ setting and in a Phase 1/2 clinical trial in the 2L setting, as well as a second pivotal trial, PiNACLE-H2H, which is a Phase 3 head-to-head CAR T cell therapy randomized controlled trial of ronde-cel for LBCL in the 2L setting for the treatment of large B-cell lymphoma; and LYL273, a GCC-targeted CAR T-cell product candidate enhanced with CD19 CAR expression and controlled cytokine release designed to improve CAR T-cell expansion, immune cell infiltration, and cancer cell killing in the hostile solid tumor microenvironment, which is in Phase 1 clinical trial for the treatment of refractory metastatic colorectal cancer. The company develops therapies using various approaches, such as c-Jun overexpression and NR4A3 gene knockout, to endow functional resistance to exhaustion; Epi-R to generate population of stem-like T cells with reduced exhaustion and improved proliferation and antitumor activity; and CD62L positive enrichment to generate CAR T cells with enhanced antitumor activity. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.

Headline News

Tue, 11 Aug 2026
Lyell Immunopharma (LYEL) COO auto-sells 89 shares for RSU tax withholding - Stock Titan

Tue, 11 Aug 2026
Lyell Immunopharma (LYEL) CEO sells shares to cover RSU tax withholding - Stock Titan

Sat, 08 Aug 2026
Possible Signal As Lyell Immunopharma Insiders Sell US$527k In Stock - simplywall.st

Wed, 22 Jul 2026
Stifel initiates Lyell Immunopharma stock with buy, $44 target - Investing.com

Thu, 02 Jul 2026
Wall Street Analysts Think Lyell Immunopharma (LYEL) Could Surge 176.02%: Read This Before Placing a Bet - Yahoo Finance

Thu, 25 Jun 2026
LYEL Forecast — Price Target — Prediction for 2027 - TradingView

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Outperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Neutral
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Neutral
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out -73 (M)
Shares Float 0 (M)
Held by Insiders 2.451e+007 (%)
Held by Institutions 1.215e+007 (%)
Shares Short 0 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS 27000
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) -12.69
Profit Margin 0 %
Operating Margin -1 %
Return on Assets (ttm) 183 %
Return on Equity (ttm) 425 %
Qtrly Rev. Growth -93.3 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) 0
Qtrly Earnings Growth -1.8094e+008 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow 0 (M)
Stock Valuations
PE Ratio 0
PEG Ratio 0
Price to Book value -1.19
Price to Sales 0
Price to Cash Flow 0
Stock Dividends
Dividend 1.23e+006
Forward Dividend 1.22e+006
Dividend Yield 8197270%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android